GE Healthcare has launched its Vscan Air SL handheld wireless ultrasound imaging system designed for use in rapid cardiac and vascular assessments to accelerate diagnoses and treatment decisions. The device features the company’s proprietary SignalMax and XDclear imaging performance technology which enables high levels of penetration, resolution, and sensitivity with a single crystal transducer technology.
The Vscan Air has two flexible, wireless, dual-probe handheld options. The new SL version includes a sector-phased array transducer for rapid cardiac assessments. The Vscan Air CL, which came out in 2021, includes a curved array transducer for abdominal imaging and obstetric assessments.
“Uniquely, both models also include a linear array transducer bringing shallow and deep scanning together on a single dual probe device suitable for a wide range of assessments,” according to GE. “Both models provide a flexible, lightweight, wireless device that delivers crystal clear images anytime, anywhere to help accelerate diagnoses and treatment decisions. The Vscan Air app, available on Android and iOS devices, allows for the secure viewing of images on a mobile device so clinicians can take Vscan Air with them to every patient.”
Since cardiovascular disease often presents itself in emergency situations, the company said that the portable and wireless nature of the device enables clinicians to efficiently collect and view images at point-of-care, streamlining workflows and avoiding potential overloads to traditional radiology resources.
“Vscan Air SL enables clinicians to make quick cardiac assessments and adds to our broad portfolio of ultrasound technologies to help further inform clinical decision making at the point of care,” said Dietmar Seifriedsberger, global general manager, point of care and handheld ultrasound at GE HealthCare, in a press release. “This newest innovation demonstrates our commitment to providing integrated solutions resulting in better standard of care delivery — and ultimately helping clinicians improve patient outcomes.”
Vscan Air SL is commercially available in multiple countries in Europe and Asia, as well as in Australia and New Zealand. The device has been cleared by FDA through the 510(k) regulatory pathway and will be commercially available this quarter, according to GE.